OptiBiotix Health (GB:OPTI) has released an update.
OptiBiotix Health PLC, a life sciences company targeting obesity, cardiovascular disease, diabetes, and skincare, has announced progress in its commercial strategy, highlighting the success of its product SlimBiome®. The natural weight management product has been gaining traction as an alternative or complementary solution to anti-obesity drugs, with high sales on Amazon UK and interest from US companies. OptiBiotix is also expanding its reach in major international markets, focusing on ecommerce and final product sales, including a new order from a NASDAQ listed US company for a tomato soup product featuring their compounds.
For further insights into GB:OPTI stock, check out TipRanks’ Stock Analysis page.
